Allogene Therapeutics Files Q1 2025 10-Q
Ticker: ALLO · Form: 10-Q · Filed: May 13, 2025 · CIK: 1737287
| Field | Detail |
|---|---|
| Company | Allogene Therapeutics, Inc. (ALLO) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotechnology, financials, SEC filing
Related Tickers: ALLO
TL;DR
ALLO Q1 2025 10-Q filed. Financials and ops update.
AI Summary
Allogene Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company, based in South San Francisco, CA, operates in the biological products sector. Key financial data and operational details for the first quarter of 2025 are presented in this filing.
Why It Matters
This filing provides investors and analysts with the latest financial performance and operational updates for Allogene Therapeutics, crucial for assessing the company's current standing and future prospects in the biotechnology sector.
Risk Assessment
Risk Level: medium — Biotechnology companies like Allogene Therapeutics are inherently subject to significant risks related to research and development, clinical trials, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 2025-05-13 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
- 2024-12-31 — Prior Year End Date (Provides a comparison point for financial data from the end of the previous fiscal year.)
Key Players & Entities
- Allogene Therapeutics, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- South San Francisco, CA (location) — Company headquarters
- 2836 (number) — Standard Industrial Classification code for Biological Products
- 001-38693 (number) — SEC file number
FAQ
What is the primary business of Allogene Therapeutics, Inc.?
Allogene Therapeutics, Inc. is primarily involved in the biological products sector, specifically with a Standard Industrial Classification code of 2836 (Biological Products, Not Elsewhere Classified).
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended March 31, 2025.
Where is Allogene Therapeutics, Inc. headquartered?
Allogene Therapeutics, Inc. is headquartered at 210 East Grand Avenue, South San Francisco, CA 94080.
What is the SEC file number for Allogene Therapeutics, Inc.?
The SEC file number for Allogene Therapeutics, Inc. is 001-38693.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted to the SEC on May 13, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Allogene Therapeutics, Inc. (ALLO).